NCT03984188View on ClinicalTrials.gov

Effectiveness of Low-Dose Theophylline for the Management of Biomass-Associated COPD

PHASE3CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

February 23, 2021

Primary Completion Date

October 17, 2023

Study Completion Date

December 15, 2023

Conditions
COPDCOPD ExacerbationCOPD Exacerbation AcutePollution Related Respiratory DisorderPollution; Exposure
Interventions
DRUG

Theophylline ER

200 mg extended release (ER) low-dose theophylline taken orally daily

DRUG

Placebo oral tablet

Manufactured methylcellulose placebo tablet taken orally daily

OTHER

Standard of Care Treatment

Per World Health Organization (WHO) guidelines for management of Chronic Obstructive Pulmonary Disease (COPD) treatment

Trial Locations (2)

Unknown

Makerere Lung Institute, Kampala

Nakaseke Hospital, Nakaseke

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

University of Miami

OTHER

NCT03984188 - Effectiveness of Low-Dose Theophylline for the Management of Biomass-Associated COPD | Biotech Hunter | Biotech Hunter